• ImmuPharma is one of the leading specialist drug development companies listed on AIM of the LSE

Significant highlights

Developing innovative drugs

ImmuPharma PLC is one of the leading specialist drug development companies listed on AIM of the LSE. Our corporate strategy and business model differentiates us from many of our peers.

We have UK, French and Swiss operations and have a formal research collaboration with Europe’s largest fundamental research organization in Europe, the Centre National de la Recherche Scientifique (CNRS).  ImmuPharma has received to-date $45 million from a corporate deal with a US pharmaceutical company and a number of grants from French government organisations for three of our drug candidates

We have a partnership-based business model, a small core of full time staff, a low R&D cost base, a strong balance sheet and diversified compounds and pipeline.

ImmuPharma has had loyal and supportive shareholders since its listing on AIM that have supported the Company through its history and has helped finance product development.

Share Price

Market Cap

Nominated Adviser ‘NOMAD’
SPARK Advisory Partners Limited
www.sparkadvisorypartners.com

Joint Broker
Stanford Capital Partners Limited
enquiries@stanfordcp.co.uk

Joint Broker
Si Capital Limited
info@sicapital.co.uk

Public Relations & Investor Relations
lisa.baderoon@immupharma.com

Professional advisers

Auditors
Nexia Smith & Williamson Audit Limited
London, U.K.

Legal Representatives
Bircham Dyson Bell LLP
London, U.K.

Badertscher Rechtsanwälte AG
Zurich, Switzerland

Company Secretary
Ewa Flynn

Patent Agents
McCarter & English, LLP, Connecticut, USA
Cabinet Regimbeau, Paris, France
Grosset-Fournier & Demachy, Paris, France

Manufacturers
Under contract with a leading manufacturer in the peptides field

“Over the last year, ImmuPharma has continued to progress Lupuzor™ toward its international Phase 3 trial in conjunction with its partner, Avion Pharmaceuticals. In addition, the Company has been active in repositioning and further developing its key assets in the earlier stage development portfolio, including programmes being run in its wholly-owned subsidiary Ureka Pharma SAS.

With my appointment as CEO, leading ImmuPharma through this next significant period, I am determined, working with the excellent team around me, in building shareholder value by progressing the development and commercialisation of all the key assets in our portfolio.”

 

 

Tim McCarthy, Chief Executive Officer PLC

30 July 2021

To contact us click here